ALK I1171N
|
NSCLC
|
ALK I1171N
|
NSCLC
|
alectinib Resistant: C3 – Early Trials
|
alectinib Resistant: C3 – Early Trials
|
ALK I1171N
|
NSCLC
|
ALK I1171N
|
NSCLC
|
ceritinib Resistant: C4 – Case Studies
|
ceritinib Resistant: C4 – Case Studies
|
ALK I1171N
|
NSCLC
|
ALK I1171N
|
NSCLC
|
crizotinib Resistant: C4 – Case Studies
|
crizotinib Resistant: C4 – Case Studies
|
ALK I1171N
|
Diffuse Large B Cell Lymphoma
|
ALK I1171N
|
Diffuse Large B Cell Lymphoma
|
lorlatinib Sensitive: C4 – Case Studies
|
lorlatinib Sensitive: C4 – Case Studies
|